Viewing Study NCT05379803


Ignite Creation Date: 2025-12-24 @ 7:15 PM
Ignite Modification Date: 2025-12-25 @ 4:52 PM
Study NCT ID: NCT05379803
Status: RECRUITING
Last Update Posted: 2024-09-19
First Post: 2022-05-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Sponsor: Hunan Province Tumor Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module